The large randomized phase III IPASS trail indicated a beneficial effect on progression-free survival (PFS) in the NSCLC patients with EGFR mutation treated with gefitinib compared to patients treated with chemotherapy.4,5 Suppression of EGFR via Gefitinib impacts multiple signaling pathways involved in tumor proliferation such as the PI3K/AKT pathway.4–6 Despite the promising anti-NSCLC effects, almost all patients underwent EGFR-TKIs resistance sooner or later. This evidence concerns the gene EGFR and neoplasm.